Cannabix Technologies Provides Update on Marijuana Breathalyzer Development
January 23 2018 - 8:30AM
Cannabix Technologies Inc. (CSE:BLO) (OTC PINK:BLOZF) (the “Company
or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for
law enforcement and the workplace, is pleased to report development
of its “Beta 3.0” (Cannabix Marijuana Breathalyzer) prototype
device based on its FAIMS- (field asymmetric waveform ion mobility
spectrometry) has been proceeding at a robust pace and is now
complete. This device is designed to operate both independently or
coupled in tandem directly to a conventional Quadrupole Mass
Spectrometer (MS) device used in forensic labs.
The Beta 3.0 prototype incorporates several key technological
improvements which include enhancements to the ion source which,
for portability, has been reduced in size with sustained stability,
providing improvements to transmission and overall device
sensitivity. The Beta 3.0 prototype also incorporates its own
tunable self-contained detector which can be used in both
independent FAIMS operation or in “pass-through” mode for tandem
coupling directly with a MS device.
Chief Scientific Officer, Dr. Raj Attariwala, states, “With
completion of the modular Beta 3.0 prototype, Cannabix has achieved
several key developmental milestones allowing this technology to be
directly tested against the accepted laboratory standard of mass
spectrometry”.
The Company has performed preliminary bench testing with the
Beta 3.0 prototype and has successfully detected THC using the
device in stand-alone mode with tandem MS analysis demonstrating
direct correlation. This is a significant developmental milestone
which the Company will use to optimize and characterize the
device’s performance measures both independently and coupled to
MS.
Cannabix has been on the leading edge in innovation with FAIMS
technology built upon the current technique of MS for measuring
THC. MS is considered the gold standard in toxicology in the
analysis of drugs, poisons, and metabolites, due to its superior
specificity and sensitivity. It is anticipated that any marijuana
breathalyzer product will need to have its results be secondarily
confirmed by independent MS. Recent work by Company scientists and
engineers to allow the Cannabix Marijuana breathalyzer to easily
couple to conventional MS equipment used in toxicology labs
everywhere is a significant achievement.
About Cannabix Technologies Inc
Cannabix Technologies Inc. is a leader in marijuana breathalyzer
development for law enforcement and the workplace. Cannabix has
established breath testing technologies in the pursuit of bringing
durable, portable hand-held tools to market to enhance detection of
marijuana impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects use days or even weeks earlier.
The devices will also be useful for other practical applications
such as testing employees in the workplace where intoxication by
THC can be hazardous.
We seek Safe Harbor. On behalf of the Board of
Directors
“Rav Mlait”
CEOCannabix Technologies Inc.
For further information, contact the Company at
info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that
involves various risks and uncertainties regarding future events.
Such forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company’s plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing “patent pending” technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Apr 2023 to Apr 2024